News >

BCMA Antibody-Drug Conjugate Continues to Extend PFS in Relapsed/Refractory Myeloma

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 22, 2019

Hal Barron, MD

Hal Barron, MD

The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 (BMA117159) study.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x